The Court of Appeals (CA) has denied the motion for reconsideration filed by French drugmaker Sanofi Pasteur Inc. over the ...

Due to the plethora of investment options such as equities, bonds, and mutual funds that are available today, picking the ...

The government’s antitrust watchdog on Friday sued three massive health conglomerates, accusing their drug middlemen of forcing insulin prices to skyrocket since 2012. The Federal Trade Commission ...

Sanofi (SNY) has won bindings bids for its consumer health division from private equity firms CD&R and PAI Partners. Read ...

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of ...

Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers ...

In a landmark move, the FTC filed a lawsuit targeting the “Big Three” PBMs: CVS Health’s Caremark Rx, Cigna’s Express Scripts (ESI), and UnitedHealth Group’s OptumRx. The suit also includes their ...

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

Sanofi's (SNY) plans to seperate its consumer care unit draws buyout bids with over €10B in funding committed from banks and ...

Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.

Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma's next chief ...